PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.35 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -65.63%. A quarter ago, it was expected that this company would post a loss of $0.41 per share when it actually produced a loss of $0.38, delivering a surprise of +7.32%.Over the last four quarters, the c ...

PROCEPT BioRobotics (NasdaqGM:PRCT) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsKevin Waters - EVP and CFOLarry L. Wood - President and CEOMatt Bacso - VP of Investor RelationsStephanie Piazzola - VP of Equity Research and Medical TechnologyConference Call ParticipantsBrandon Vazquez - Research AnalystChris Pasquale - Partner and Senior Analyst of Medical Devices and SuppliesDanielle Antalffy - Senior AnalystJosh Jennings - Managing Director and Senior AnalystMatthew O'Brien - Ma ...

PROCEPT BioRobotics (NasdaqGM:PRCT) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsKevin Waters - CFOLarry Wood - CEOMatt Bacso - VP of Investor RelationsStephanie Piazzola - VP of Equity Research and Medical TechnologyConference Call ParticipantsBrandon Vazquez - Research AnalystChris Pasquale - Partner and Senior Analyst of Medical Devices and SuppliesDanielle Antalffy - Senior AnalystJosh Jennings - Managing Director and Senior AnalystMatthew O'Brien - Managing Director and Senio ...

PROCEPT BioRobotics (NasdaqGM:PRCT) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Speaker12Good afternoon, welcome to the PROCEPT BioRobotics fourth quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. We will be facilitating a question and answer session toward the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the conference over to Matt Bacso, Vice President, Investor Relations, for a few intr ...

"In the fourth quarter, we delivered our highest procedure volume to date—approximately 12,200—and sold 65 new systems, marking our strongest capital quarter," said Larry Wood, Chief Executive Officer. "At the same time, we took meaningful steps to position the Company for its next phase of growth. To sharpen our focus on delivering durable procedure growth, we realigned our commercial organization, established a dedicated launch team to reduce activation variability, and implemented a more disciplined hand ...

SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended December 31, 2025. “In the fourth quarter, we delivered our highest procedure volume to date—approximately 12,200—and sold 65 new systems, marking our strongest capital quarter,” said Larry Wood, Chief Executive Offic ...

We came across a bullish thesis on PROCEPT BioRobotics Corporation on Notes From The Beauty Contest’s Substack by Crashkolnikov. In this article, we will summarize the bulls’ thesis on PRCT. PROCEPT BioRobotics Corporation's share was trading at $29.21 as of February 9th. Is Intuitive Surgical’s (ISRG) Valuation Limiting Further Upside After Earnings? Master Video/Shutterstock.com PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in t ...

SAN JOSE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that it has updated the timing of its previously announced fourth quarter 2025 earnings conference call and Investor Day due to significant travel disruptions caused by inclement weather. The Company will report financial results for the fourth quarter of 2025 after ...

​PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is one of the Overlooked Small Cap Stocks to Buy Now. Wall Street is positive on PROCEPT BioRobotics Corporation (NASDAQ:PRCT) ahead of its fiscal Q4 2025 earnings, expected to be released on February 24, 2026. The Street expects the company to post quarterly revenue of around $372.87 million and a GAAP EPS of $1.56. ​Recently, on January 26, Ryan Zimmerman from BTIG maintained a Hold rating on the stock without disclosing any price targets. Earlier on Decemb ...

Core Insights - PROCEPT BioRobotics is focused on advancing patient care in urology through transformative robotic solutions [3] - The company will present at two investor conferences in March 2026, indicating active engagement with the investment community [1][2] Company Overview - PROCEPT BioRobotics aims to revolutionize the treatment of Benign Prostatic Hyperplasia (BPH) globally by partnering with urologists [3] - The company manufactures the AQUABEAM® and HYDROS® Robotic Systems, with the HYDROS system being the only AI-powered technology delivering Aquablation therapy [3] - Aquablation therapy is designed to provide effective, safe, and durable outcomes for men suffering from lower urinary tract symptoms (LUTS) due to BPH, regardless of prostate size, shape, or surgeon experience [3] - BPH affects approximately 40 million men in the United States, highlighting a significant market opportunity for the company [3] Upcoming Events - The company will participate in the TD Cowen 46th Annual Health Care Conference and the 2026 Leerink Global Health Care Conference [2] - A live webcast of each event will be available on the company's website, with recordings archived for at least 90 days [2] - Specific event details include a fireside chat on March 2 at 11:40 am ET in Boston, MA, and another on March 10 at 8 am ET in Miami, FL [4]